cDNA Microarrays In Gene Expression Of Uveitis Patients

眼部炎症性疾病，包括葡萄膜炎，会导致严重的视力丧失。以前的非人类研究已经确定了几种细胞类型、受体系统和代谢中间体，这些细胞类型、受体系统和代谢中间体导致了人类患者的治疗方法。然而，关于这些步骤在明确的炎症性疾病状态下的人类基因表达的信息缺乏。这项非干预性研究建议从参加其他眼部炎症性疾病壁间试验的患者身上获取外周血液和组织样本，并应用当代基因芯片技术来分析差异基因表达。测试结果不会报告给参与者，也不会用于诊断或治疗目的。研究？S的主要目标是利用基因芯片分析，确定眼部炎症性疾病患者在特定临床阶段的独特基因表达谱以及疾病相关基因。这将有助于进一步了解其病理机制和潜在的治疗靶点。大约3,000-5,000个基因将从与白介素蛋白(IL)及其受体和肿瘤坏死因子(TNF)相关的选定集合开始进行检查。纯化的外周血单核细胞(或使用RNA分离程序的全血裂解物)将用于从这些样本中分离总RNA。样本将在炎症性疾病活动期或复发期以及治疗后的静止期再次采集。基因分析的微阵列工具和方法现已在NEI获得。与这些研究相结合的是负调控细胞的功能分析和细胞表面标记，即所谓的抑制细胞。这些研究目前主要集中在CD25+T细胞比例和某些T细胞活化的标志物，如GITR。T细胞激活与这些负调控信号和临床活动之间存在相关性。

Ocular inflammatory diseases, including uveitis, cause significant visual loss. Previous non-human investigations have identified several cell types, receptor systems and metabolic intermediates that have led to treatment approaches for human patients. However,information on the human genetic expression of these steps in defined inflammatory disease states is lacking. This non-intervention study proposes to obtain peripheral blood and tissue specimens from patients enrolled in other intramural trials for ocular inflammatory diseases and to apply contemporary cDNA microarray technologies for the analysis of differential gene expression. Test results will not be reported to participants or used for diagnostic or therapeutic purposes.The study?s primary objective is to identify unique gene expression profiles as well as disease relevant genes for patients with ocular inflammatory disease at defined clinical stages using cDNA microarray analysis. This will help provide further insight to understand the pathological mechanisms and potential targets for treatment. Some 3,000-5,000 genes will be examined starting with a selected set associated with interleukin (IL) proteins and their receptors, and with tumor necrosis factors (TNF). Purified peripheral blood mononuclear cells (or whole blood lysates using RNA isolation procedures) will be used to isolate total RNA from these samples. Samples will be taken during periods of active or recurring inflammatory disease and again during periods of quiescence after treatment. The microarray tools and methods for genetic analysis are now available at the NEI.In conjunction with these studies are functional assays and cell surface markers of negative regulatory cells, so called ?suppressor cells?. These studies center for the moment on the CD25+ T cell fraction and certain markers of T cell activation such as GITR. A correlation is being made between T cell activation and these negative regulatory signals and clinical activity.